Zobrazeno 1 - 10
of 36
pro vyhledávání: '"R. L. Lins"'
Publikováno v:
Pesquisas E Avanços Em Genética E Biologia Molecular ISBN: 9786599965807
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ea6ed63c598da77738c24545f1a3ad6
https://doi.org/10.53934/9786585062046-11
https://doi.org/10.53934/9786585062046-11
Autor:
Marie-Paule Emonds, Pierre Zachee, Ronald Daelemans, Marc Boogaerts, Willy Goossens, R L Lins
Publikováno v:
Scopus-Elsevier
Autor:
Juerg Nussberger, R. L. Lins, Roland E. Schmieder, Yanntong Chiang, Alan H. Gradman, Margaret F. Prescott
Publikováno v:
International Journal of Clinical Practice. 61:1461-1468
Summary Background: Aliskiren is the first in a new class of orally effective renin inhibitors for the treatment of hypertension. Methods: In 569 patients with mild-to-moderate hypertension, blood pressure (BP), plasma renin activity (PRA) and plasma
Autor:
Deutsch Paul J, R. Haesen, Liwen Xi, G. Mistry, Michael Hesney, Jacqueline B. McCrea, Chester J. Kitchen, S. Holland, Scott A. Waldman, R. L. Lins, Howard E. Greenberg, J.D. Rogers, Kimberly L. Birk, A. K. Majumdar, S. X. Li, Robert A. Blum, Donald G. Musson
Publikováno v:
Antimicrobial Agents and Chemotherapy. 46:3506-3511
Ertapenem (INVANZ) is a new once-a-day parenteral β-lactam antimicrobial shown to be effective as a single agent for treatment of various community-acquired and mixed infections. The single- and multiple-dose pharmacokinetics of ertapenem at doses u
Autor:
A. Van Peer, E. Snoeck, Meindert Danhof, V. Piotrovskij, J. Heykants, R L Lins, P. Jacqmin, A G Dupont, R. Van Gool, Robert Woestenborghs
Publikováno v:
European journal of clinical pharmacology
Vrije Universiteit Brussel
Vrije Universiteit Brussel
Objective: The pharmacokinetics and non-linear red blood cell partitioning of the nucleoside transport inhibitor draflazine were investigated in 19 healthy male and female subjects (age range 22–55 years) after a 15-min i.v. infusion of 1 mg, immed
Autor:
M. M.-L. Janssens, R. L. Lins
Publikováno v:
Journal of International Medical Research. 23:167-174
This randomized, double-blind, double-dummy, parallel-group trial was initiated to evaluate and compare the tolerability of once-daily astemizole-D capsules (10 mg astemizole/240 mg pseudoephedrine) and twice-daily loratadine-D tablets (5 mg loratadi
Publikováno v:
Drug Investigation. 2:214-218
In a double-blind placebo-controlled randomised crossover study, the antihypertensive activity and tolerability of 2 combination preparations, containing a diuretic and a potassium-sparing agent, were evaluated in the treatment of essential hypertens
Publikováno v:
International journal of clinical practice. 61(9)
Aliskiren is the first in a new class of orally effective renin inhibitors for the treatment of hypertension.In 569 patients with mild-to-moderate hypertension, blood pressure (BP), plasma renin activity (PRA) and plasma renin concentration (PRC) wer
Publikováno v:
International journal of clinical pharmacology and therapeutics. 45(1)
Objective: Concentrations in saliva, as an alternative to concentrations in blood, can be advantageous for the monitoring of antiepileptic agents. This study assesses the relationship between saliva and plasma concentrations of levetiracetam after ad
Publikováno v:
Update in Intensive Care and Emergency Medicine ISBN: 9783642792465
Acute renal failure in the clinically ill / Bellomo, R. [edit.]
Acute renal failure in the clinically ill / Bellomo, R. [edit.]
Acute renal failure (ARF) is a syndrome, not a disease. It has numerous causes and occurs in a wide range of patients, making the evaluation of prognosis very difficult. The most accurate outcome measure is the mortality rate. That of acute renal fai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26c3b630d0e706496aa207190cc996dc
https://doi.org/10.1007/978-3-642-79244-1_7
https://doi.org/10.1007/978-3-642-79244-1_7